Cargando…

Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study

OBJECTIVES: We compared long-term outcomes in patients with atrial fibrillation (AF) with and without a secondary precipitant. DESIGN AND SETTING: Retrospective cohort study based on Danish nationwide registries. PARTICIPANTS: Patients with AF with and without secondary precipitants (1996–2015) were...

Descripción completa

Detalles Bibliográficos
Autores principales: Gundlund, A, Kümler, Thomas, Bonde, Anders Nissen, Butt, Jawad Haider, Gislason, Gunnar Hilmar, Torp-Pedersen, Christian, Køber, Lars, Olesen, Jonas Bjerring, Fosbøl, Emil Loldrup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756362/
https://www.ncbi.nlm.nih.gov/pubmed/31542739
http://dx.doi.org/10.1136/bmjopen-2018-028468
_version_ 1783453384288763904
author Gundlund, A
Kümler, Thomas
Bonde, Anders Nissen
Butt, Jawad Haider
Gislason, Gunnar Hilmar
Torp-Pedersen, Christian
Køber, Lars
Olesen, Jonas Bjerring
Fosbøl, Emil Loldrup
author_facet Gundlund, A
Kümler, Thomas
Bonde, Anders Nissen
Butt, Jawad Haider
Gislason, Gunnar Hilmar
Torp-Pedersen, Christian
Køber, Lars
Olesen, Jonas Bjerring
Fosbøl, Emil Loldrup
author_sort Gundlund, A
collection PubMed
description OBJECTIVES: We compared long-term outcomes in patients with atrial fibrillation (AF) with and without a secondary precipitant. DESIGN AND SETTING: Retrospective cohort study based on Danish nationwide registries. PARTICIPANTS: Patients with AF with and without secondary precipitants (1996–2015) were matched 1:1 according to age, sex, calendar year, CHA(2)DS(2)-VASc score and oral anticoagulation therapy (OAC), resulting in a cohort of 39 723 patients with AF with a secondary precipitant and the same number of patients with AF without a secondary precipitant. Secondary precipitants included alcohol intoxication, thyrotoxicosis, myocardial infarction, surgery and infection in conjunction with AF. PRIMARY AND SECONDARY OUTCOMES: The primary outcome in this study was thromboembolic events. Secondary outcomes included AF rehospitalisation and death. Long-term risks of outcomes were examined by multivariable Cox regression analysis. RESULTS: The most common precipitants were infection (55.0%), surgery (13.2%) and myocardial infarction (12.0%). The 5-year absolute risk of thromboembolic events (taking death into account as a competing risk) in patients with AF grouped according to secondary precipitants were 8.3% (alcohol intoxication), 8.5% (thyrotoxicosis), 12.1% (myocardial infarction), 11.6% (surgery), 12.2% (infection), 10.1% (>1 precipitant) and 12.3% (no secondary precipitant). In the multivariable analyses, AF with a secondary precipitant was associated with the same or an even higher thromboembolic risk than AF without a secondary precipitant. One exception was patients with AF and thyrotoxicosis: those not initiated on OAC therapy carried a lower thromboembolic risk the first year of follow-up than matched patients with AF without a secondary precipitant and no OAC therapy. CONCLUSIONS: In general, AF with a secondary precipitant was associated with the same thromboembolic risk as AF without a secondary precipitant. Consequently, this study highlights the need for more research regarding the long-term management of patients with AF associated with a secondary precipitant.
format Online
Article
Text
id pubmed-6756362
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-67563622019-10-07 Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study Gundlund, A Kümler, Thomas Bonde, Anders Nissen Butt, Jawad Haider Gislason, Gunnar Hilmar Torp-Pedersen, Christian Køber, Lars Olesen, Jonas Bjerring Fosbøl, Emil Loldrup BMJ Open Cardiovascular Medicine OBJECTIVES: We compared long-term outcomes in patients with atrial fibrillation (AF) with and without a secondary precipitant. DESIGN AND SETTING: Retrospective cohort study based on Danish nationwide registries. PARTICIPANTS: Patients with AF with and without secondary precipitants (1996–2015) were matched 1:1 according to age, sex, calendar year, CHA(2)DS(2)-VASc score and oral anticoagulation therapy (OAC), resulting in a cohort of 39 723 patients with AF with a secondary precipitant and the same number of patients with AF without a secondary precipitant. Secondary precipitants included alcohol intoxication, thyrotoxicosis, myocardial infarction, surgery and infection in conjunction with AF. PRIMARY AND SECONDARY OUTCOMES: The primary outcome in this study was thromboembolic events. Secondary outcomes included AF rehospitalisation and death. Long-term risks of outcomes were examined by multivariable Cox regression analysis. RESULTS: The most common precipitants were infection (55.0%), surgery (13.2%) and myocardial infarction (12.0%). The 5-year absolute risk of thromboembolic events (taking death into account as a competing risk) in patients with AF grouped according to secondary precipitants were 8.3% (alcohol intoxication), 8.5% (thyrotoxicosis), 12.1% (myocardial infarction), 11.6% (surgery), 12.2% (infection), 10.1% (>1 precipitant) and 12.3% (no secondary precipitant). In the multivariable analyses, AF with a secondary precipitant was associated with the same or an even higher thromboembolic risk than AF without a secondary precipitant. One exception was patients with AF and thyrotoxicosis: those not initiated on OAC therapy carried a lower thromboembolic risk the first year of follow-up than matched patients with AF without a secondary precipitant and no OAC therapy. CONCLUSIONS: In general, AF with a secondary precipitant was associated with the same thromboembolic risk as AF without a secondary precipitant. Consequently, this study highlights the need for more research regarding the long-term management of patients with AF associated with a secondary precipitant. BMJ Publishing Group 2019-09-20 /pmc/articles/PMC6756362/ /pubmed/31542739 http://dx.doi.org/10.1136/bmjopen-2018-028468 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Cardiovascular Medicine
Gundlund, A
Kümler, Thomas
Bonde, Anders Nissen
Butt, Jawad Haider
Gislason, Gunnar Hilmar
Torp-Pedersen, Christian
Køber, Lars
Olesen, Jonas Bjerring
Fosbøl, Emil Loldrup
Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study
title Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study
title_full Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study
title_fullStr Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study
title_full_unstemmed Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study
title_short Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—Danish nationwide cohort study
title_sort comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant—danish nationwide cohort study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756362/
https://www.ncbi.nlm.nih.gov/pubmed/31542739
http://dx.doi.org/10.1136/bmjopen-2018-028468
work_keys_str_mv AT gundlunda comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy
AT kumlerthomas comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy
AT bondeandersnissen comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy
AT buttjawadhaider comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy
AT gislasongunnarhilmar comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy
AT torppedersenchristian comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy
AT køberlars comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy
AT olesenjonasbjerring comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy
AT fosbølemilloldrup comparativethromboembolicriskinatrialfibrillationwithandwithoutasecondaryprecipitantdanishnationwidecohortstudy